New York, NY

Harlem Prevention Center

Acquired Immunodeficiency Syndrome

Substance-Related Disorders

Mpox (monkeypox)

HIV Infections

Tecovirimat

Columbia University

National Institute of Allergy and Infectious Diseases (NIAID)

condition

allSponsorName

SIGA Technologies

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

A5418 is a randomized, placebo-controlled, double-blind study to establish the efficacy of tecovirimat for the treatment of people with laboratory-confirmed or presumptive HMPXV disease.

Study of Tecovirimat for Human Mpox Virus

Harlem Prevention Center | New York, NY

Site insights

Work at this site?

Active trials

Study of Tecovirimat for Human Mpox Virus (STOMP)

Trial sponsors